The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.85
Bid: 4.70
Ask: 5.00
Change: 0.00 (0.00%)
Spread: 0.30 (6.383%)
Open: 4.85
High: 4.85
Low: 4.85
Prev. Close: 4.85
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of AGM, investor conference & Accounts

7 Jun 2021 15:28

RNS Number : 0754B
Eden Research plc
07 June 2021
 

7 June 2021

 

Eden Research Plc

("Eden" or "Company")

 

Notice of AGM, virtual investor conference and 2020 Accounts

 

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces that its Notice of the Annual General Meeting ("AGM") has been issued to shareholders and is now available on the Company's website: www.edenresearch.com 

The AGM is to be held on Wednesday 30 June 2021 at 12.00pm at 67C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RQ.

In accordance with current Government regulations in relation to COVID-19, shareholders are encouraged to submit their Form of Proxy in advance of the General Meeting and are strongly discouraged from attending the General Meeting in person to safeguard the Company's shareholders' and employees' health, to comply with current Government guidelines, to minimise the unnecessary movement of people and to make the AGM as safe and efficient as possible.

Should shareholders wish to ask any questions in relation to the Resolutions, which they may otherwise have asked at the AGM, had they been in attendance, they are encouraged to contact the Company prior to the AGM by email at agm@edenresearch.com.

Virtual Investor Conference

Given the advised restrictions in place for the AGM due to COVID-19, the Company shall be holding a virtual investor conference at 1pm on 30 June 2021, where the executive team at Eden shall make a presentation to shareholders and other interested parties and shall answer questions that have been submitted to the Board ahead of time. Should you have any questions for the Board, please send them by email to agm@edenresearch.com by 5pm on Friday 25 June 2021.

Details of how to join the virtual investor conference shall follow in due course.

 

2020 Accounts

 

In addition, and following discussions with the Company's auditors and regulatory guidance in relation to the ongoing COVID-19 pandemic, the Company has received an extension to the timeline for filing its 2020 Accounts at Companies House. Accordingly, the Company's consolidated accounts for the year ended 31 December 2020 (the "2020 Accounts") will not be presented at the AGM.

 

The Company continues to work with its auditors to finalise its 2020 Accounts and, when available, the Company will issue an RNS and dispatch the annual report and accounts to shareholders. At that stage the Company intends to call a further general meeting to receive the annual report and accounts.

 

 

 

For further information contact:

 

Eden Research plc

www.edenresearch.com

Sean SmithAlex Abrey

01285 359 555

 

Cenkos Securities plc (Nominated advisor and broker)

Giles Balleny / Camilla Hume/ Mark Connelly (corporate finance)Michael Johnson (sales)

020 7397 8900

 

Hawthorn Advisors (Financial PR)

Lorna Cobbett / Victoria Ainsworth

eden@hawthornadvisors.com

 

 

 

 

 

 

Notes to Editors:

 

Eden Research is an AIM quoted company that develops and supplies breakthrough biopesticide products and natural, plastic-free microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden has numerous patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. Eden was admitted to trading on AIM in May 2012.

 

For more information about Eden, please visit: www.edenresearch.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOASSWFLWEFSEEM
Date   Source Headline
24th Sep 20187:00 amRNSHalf-year Report
13th Jul 201810:23 amRNSDirector/PDMR Shareholding
21st Jun 20184:44 pmRNSResult of AGM
21st Jun 20187:00 amRNSAGM Statement
19th Jun 20187:00 amRNSDirector/PDMR Shareholding
14th Jun 20187:00 amRNSRegulatory Progress Update
30th May 20182:30 pmRNSPosting of Annual Report & Notice of AGM
10th May 20185:04 pmRNSDirector/PDMR Shareholding
8th May 20187:00 amRNSExercise of Options
20th Mar 20187:00 amRNSPreliminary results
11th Jan 20187:00 amRNSYear-end Trading Statement
12th Dec 20177:00 amRNSRegulatory Progress Update
29th Sep 201711:15 amRNSHalf-year Report - Replacement
29th Sep 20177:30 amRNSAdoption of New LTIP and Grant of Awards
29th Sep 20177:01 amRNSBoard Changes
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:00 amRNSApproval of MevaloneT in Portugal
1st Sep 20177:00 amRNSNotice of Results
30th Jun 20175:14 pmRNSHolding(s) in Company
30th Jun 201712:29 pmRNSResult of AGM
30th Jun 20177:43 amRNSAGM Statement
30th Jun 20177:39 amRNSCompletion of Placing & Subscription
30th Jun 20177:00 amRNSSipcam agreements, investment and proposed placing
29th Jun 20179:43 amRNSNew terms agreed with UMMS
5th Jun 20173:14 pmRNSPosting of Annual Report & Notice of AGM
22nd May 20177:00 amRNSFinal Results
11th May 20179:00 amRNSEden Research on BBC Radio 4's You & Yours
29th Mar 20177:00 amRNSExtension of patent protection in Greece
8th Mar 20172:40 pmRNSVoting Rights, Warrants and Options Outstanding
23rd Jan 20172:00 pmRNSPrice Monitoring Extension
23rd Jan 20177:00 amRNSFungicide product approved for sale in France
21st Dec 20167:01 amRNSTrading update
21st Dec 20167:00 amRNSEastman commercialisation agreement for nematicide
27th Sep 20167:00 amRNSHalf-year Report
28th Jun 201612:28 pmRNSResult of AGM
28th Jun 20167:00 amRNSAGM Statement
15th Jun 20167:00 amRNSLabel extensions for 3AEY in Spain and Greece
7th Jun 20167:00 amRNSPosting of Annual Report & Notice of AGM
26th May 20163:36 pmRNSDirector/PDMR Shareholding
24th May 20167:00 amRNSFinal Results
11th Apr 20169:31 amRNSHolding(s) in Company
30th Mar 20167:00 amRNSPlacing to raise £2.6m
22nd Feb 20167:00 amRNSApproval of 3AEY in Spain
11th Feb 20167:00 amRNSApproval of 3AEY in Italy
10th Feb 20167:00 amRNSFirst shipment of MevaloneT (3AEY) to Greece
21st Jan 20167:00 amRNSExercise of options
14th Jan 20167:00 amRNSFurther progress with EU product approvals
16th Nov 20157:00 amRNSKenya approval & first commercial-scale order
26th Oct 20157:00 amRNSAppointment of Nominated Adviser and Broker
24th Sep 20157:00 amRNSCollaboration and Licence Agreement Signed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.